[Form 4] SCHOLASTIC CORP Insider Trading Activity
Rhea-AI Filing Summary
Alix Guerrier, a director of Scholastic Corporation (SCHL), was granted 4,528 restricted stock units (RSUs) linked to the company's common stock at a reported price of $27.60 per share. The RSUs are scheduled to vest on the earlier of September 17, 2026 or the date of the company's 2026 annual stockholder meeting. After the grant, Ms. Guerrier is reported to beneficially own 10,363 shares of Scholastic common stock. This Form 4 reports the non-derivative equity award under the Amended and Restated Scholastic Corporation Outside Directors Stock Incentive Plan.
Positive
- Grant documented: 4,528 restricted stock units awarded under the Amended and Restated Scholastic Corporation Outside Directors Stock Incentive Plan
- Vesting schedule disclosed: RSUs vest on the earlier of September 17, 2026 or the company's 2026 annual stockholder meeting
- Post-grant holdings reported: Reporting person beneficially owns 10,363 shares following the transaction
Negative
- None.
Insights
TL;DR: Director received a standard outside-director RSU award scheduled to vest within roughly one year.
The grant of 4,528 restricted stock units to a director under the Outside Directors Stock Incentive Plan appears to be a routine compensation event for non-employee directors. The award vests on the earlier of a specified date or the 2026 annual meeting, which is a typical time-based vesting condition for director equity to retain service and tie compensation to continued board membership. The filing shows post-grant beneficial ownership of 10,363 shares, reflecting the director's reported holdings after this grant.
TL;DR: Transaction records a non-derivative equity grant; no derivative instruments reported and no material change to capital structure disclosed.
The Form 4 documents a non-derivative transaction (grant of RSUs) with an indicated per-share price of $27.60 and no accompanying derivative activity disclosed in Table II. The disclosure does not indicate any immediate sale or disposition. There is no information in the form that quantifies dilution impact or links the award to any performance metrics. Based solely on the filing, this is a routine director grant with limited material impact on investors.